10.02.2023 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial . Seite 1
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today
I am very pleased to announce that the latest addition to the BMC series, BMC Digital Health, has fully launched and has published its first articles. As a way of celebrating the occasion, we decided to ask the Editorial Board Members of this exciting title about their thoughts on the journal and the future of digital health.
CAMBRIDGE, Mass. & SALISBURY, England (BUSINESS WIRE) $KALV KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating.
Topline results were announced from a phase 3b trial that compared esketamine nasal spray to quetiapine extended-release in adults with treatment-resistant major depressive disorder.